Ignite Creation Date:
2024-05-06 @ 7:54 AM
Last Modification Date:
2024-10-26 @ 11:53 AM
Study NCT ID:
NCT02624570
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2020-07-15
First Post:
2015-12-03
Brief Title:
Midostaurin Access Program for Newly Diagnosed FLT3 ITD or TKD Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Acute Myeloid Leukemia AML With |
| FLT3 Mutation Internal Tandem Duplication ITD or Tyrosine Kinase Domain TKD |